FBRX
NASDAQForte Biosciences Inc.
News · 26 weeks41-57%
2026-01-182026-07-12
Mix2790d
- Insider10(37%)
- SEC Filings9(33%)
- Other7(26%)
- Earnings1(4%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECForte Biosciences Inc. filed SEC Form 8-K: Regulation FD Disclosure8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRFB102 Achieves Statistically Significant Improvement in Vitiligo at Week 24 After Completion of 12-Week Treatment PeriodStatistically Significant FB102 Benefit Observed By Day 64 and Continued through Week 24 FB102-Treated Subjects Continued Improving Through Week 24 After Completion of the 12-Week Treatment Period Supporting FB102 Mechanistic Modulation of Both IL-2– and IL-15–Dependent Pathogenic T-cell Biology while Preserving Regulatory T Cells Forte will be Hosting a Conference Call to Discuss the Results at 8:30 am ET Forte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced positive results from the FB102 double-blind placebo-controlled phase 1b study in vitiligo: FB102 achieved
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- INSIDERCHIEF FINANCIAL OFFICER Riley Antony A converted options into 375 shares and covered exercise/tax liability with 134 shares, increasing direct ownership by 0.57% to 42,600 units (SEC Form 4)4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDEROfficer Wagner Paul A. converted options into 1,250 shares and covered exercise/tax liability with 98 shares, increasing direct ownership by 1% to 85,482 units (SEC Form 4)4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by CHIEF FINANCIAL OFFICER Riley Antony A4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Officer Wagner Paul A.4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form EFFECT filed by Forte Biosciences Inc.EFFECT - Forte Biosciences, Inc. (0001419041) (Filer)
- SECSEC Form SCHEDULE 13G filed by Forte Biosciences Inc.SCHEDULE 13G - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form S-3/A filed by Forte Biosciences Inc.S-3/A - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDERSEC Form 4 filed by Director Doberstein Stephen K4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-3 filed by Forte Biosciences Inc.S-3 - Forte Biosciences, Inc. (0001419041) (Filer)
- INSIDERSEC Form 4 filed by Director Kapoor Shivpreet Singh4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Vincent Richard G4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Gryska David W4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Brun Scott C.4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- INSIDERSEC Form 4 filed by Director Kornfeld Steven4 - Forte Biosciences, Inc. (0001419041) (Issuer)
- SECSEC Form S-8 filed by Forte Biosciences Inc.S-8 - Forte Biosciences, Inc. (0001419041) (Filer)
- SECForte Biosciences Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Forte Biosciences Inc.SCHEDULE 13G/A - Forte Biosciences, Inc. (0001419041) (Subject)
- SECForte Biosciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition8-K - Forte Biosciences, Inc. (0001419041) (Filer)
- PRForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesForte Biosciences, Inc. (www.fortebiorx.com) (NASDAQ:FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the issuance of equity inducement awards as required by the Nasdaq Stock Market Rules. In accordance with NASDAQ Listing Rule 5635(c)(4), the Compensation Committee of Forte's Board of Directors approved the grant of equity awards in the form of options to purchase a total of 50,000 shares of its common stock, and restricted stock units representing 50,000 shares of its common stock, to a new non-executive employee as a material inducement to such individual accepting employment with the Company. The option award shal
- SECSEC Form 10-Q filed by Forte Biosciences Inc.10-Q - Forte Biosciences, Inc. (0001419041) (Filer)
FBRX FAQ
7 questionsWhat does Forte Biosciences Inc. do?
Forte Biosciences Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing a live biotherapeutic FB-401 that has completed Phase 1/2a clinical trial to treat inflammatory skin diseases for pediatric atopic dermatitis patients. The company was incorporated in 2007 and is based in Torrance, California.Where does FBRX stock trade?
Forte Biosciences Inc. (FBRX) is listed on NASDAQ.What sector and industry is FBRX in?
Forte Biosciences Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Forte Biosciences Inc. go public?
Forte Biosciences Inc. (FBRX) completed its IPO in 2017.What are analysts saying about FBRX?
Forte Biosciences Inc. has had 8 recent analyst actions on file. The most recent action was from Evercore ISI: Outperform on 2025-11-25. Recent price targets range from $275.00 to $350.00.What companies are similar to FBRX?
Notable peers in the same industry include LLY (Eli Lilly and Company), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.), NVS (Novartis AG). Compare FBRX side-by-side with any of them on Quantisnow.How can I track FBRX on Quantisnow?
Quantisnow aggregates Forte Biosciences Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow FBRX to receive live email and push alerts on every new disclosure.